GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Nexien BioPharma Inc (OTCPK:NXEN) » Definitions » EBIT per Share

NXEN (Nexien BioPharma) EBIT per Share : $-0.00 (TTM As of Dec. 2024)


View and export this data going back to . Start your Free Trial

What is Nexien BioPharma EBIT per Share?

Nexien BioPharma's EBIT per Share for the three months ended in Dec. 2024 was $0.00. Its EBIT per Share for the trailing twelve months (TTM) ended in Dec. 2024 was $-0.00.

During the past 3 years, the average EBIT per Share Growth Rate was 60.70% per year. During the past 5 years, the average EBIT per Share Growth Rate was 53.10% per year. Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the EBIT per Share growth rate using EBIT per Share data.

The historical rank and industry rank for Nexien BioPharma's EBIT per Share or its related term are showing as below:

NXEN' s 3-Year EBIT Growth Rate Range Over the Past 10 Years
Min: -64.5   Med: 53   Max: 60.7
Current: 60.7

During the past 8 years, the highest 3-Year average EBIT per Share Growth Rate of Nexien BioPharma was 60.70% per year. The lowest was -64.50% per year. And the median was 53.00% per year.

NXEN's 3-Year EBIT Growth Rate is ranked better than
93.31% of 822 companies
in the Drug Manufacturers industry
Industry Median: 8.3 vs NXEN: 60.70

Nexien BioPharma's EBIT for the three months ended in Dec. 2024 was $-0.02 Mil.

Nexien BioPharma EBIT per Share Historical Data

The historical data trend for Nexien BioPharma's EBIT per Share can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Nexien BioPharma EBIT per Share Chart

Nexien BioPharma Annual Data
Trend Jun17 Jun18 Jun19 Jun20 Jun21 Jun22 Jun23 Jun24
EBIT per Share
Get a 7-Day Free Trial -0.05 -0.03 -0.01 -0.01 -

Nexien BioPharma Quarterly Data
Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24
EBIT per Share Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only - - - - -

Nexien BioPharma EBIT per Share Calculation

EBIT per Share is the amount of Earnings Before Interest and Taxes (EBIT) per outstanding share of the company's stock.

Earnings Before Interest and Taxes (EBIT) is what the company earns before it expenses interest and taxes.

Nexien BioPharma's EBIT per Share for the fiscal year that ended in Jun. 2024 is calculated as

EBIT per Share(A: Jun. 2024 )
=EBIT/Shares Outstanding (Diluted Average)
=-0.156/66.194
=-0.00

Nexien BioPharma's EBIT per Share for the quarter that ended in Dec. 2024 is calculated as

EBIT per Share(Q: Dec. 2024 )
=EBIT/Shares Outstanding (Diluted Average)
=-0.024/70.766
=-0.00

EBIT per Share for the trailing twelve months (TTM) ended in Dec. 2024 adds up the quarterly data reported by the company within the most recent 12 months, which was $-0.00

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Nexien BioPharma  (OTCPK:NXEN) EBIT per Share Explanation

EBIT is a company's earnings before interest and tax expenses are deducted. It measures a company's profit generates from operating, ignoring tax burden and capital structure. As the tax expense are not deducted, EBIT is helpful when comparing companies in the same industry but with different tax situations. Also, the interest expense are included in EBIT, making it useful to compare companies that have high interest expenses due to large amount of debt.

Nexien BioPharma EBIT per Share Related Terms

Thank you for viewing the detailed overview of Nexien BioPharma's EBIT per Share provided by GuruFocus.com. Please click on the following links to see related term pages.

Nexien BioPharma Business Description

Industry
GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Nexien BioPharma Inc (OTCPK:NXEN) » Definitions » EBIT per Share
Comparable Companies
PLSH BSPK GCAN NTRR SKYI KOAN CBDY THCT KAYS PCYN ZTS XTER:MRK NSE:SUNPHARMA TSE:4502 LSE:HLN XSWX:GALD XSWX:SDZ HKSE:03692 NSE:DIVISLAB XTAE:TEVA
Traded in Other Exchanges
N/A
Address
4340 East Kentucky Avenue, Suite 206, Glendale, CO, USA, 80246
Website
https://www.nexienbiopharma.com
Nexien BioPharma Inc is a U.S.-based pharmaceutical company engaged in the formulation, development and commercialization of cannabinoid-based pharmaceuticals, in accordance with U.S. Food and Drug Administration ('FDA') pre-clinical and clinical pathways.
Executives
Jeffrey Friedland other: Former 10% Owner 4340 E KENTUCKY AVE, SUITE 206, GLENDALE CO 80246
Kanativa Usa Inc. 10 percent owner 4340 E KENTUCKY AVE, SUITE 206, GLENDALE CO 80246
Kanativa Inc. 10 percent owner 4340 E. KENTUCKY AVE., SUITE 206, GLENDALE CO 80246
Joseph F Aceto officer: VP Legal & IP Counsel 1617 NEWARK ROAD, KENNETT SQUARE PA 19348
Jeremy Robert Reeh officer: VP Translational Research 11 TANKARD LANE, WASHINGTON CROSSING PA 18977
Alexander Michael Wasyl director, officer: Chief Executive Officer 31 BEIDLER DRIVE, WASHINGTON CROSSING PA 18977
Frank J Manganella officer: VP Corporate Development 148-26 10TH AVENUE, WHITESTONE NY 11357
Clark Courtney Lynne director PO BOX 7801, ASPEN CO 81612
Lindy Snider director 408 BARBARA LANE, BRYN MAWR PA 19010
Robert I Goldfarb officer: Chief Operating Officer 230 GOLDEN BEACH DRIVE, GOLDEN BEACH FL 33160
Evan L Wasoff officer: Chief Financial Officer 101 WINGER DRIVE, NEDERLAND CO 80466
Alain D Bankier director 150 COLUMBUS AVENUE APT 17F, NEW YORK NY 10023
Richard S Greenberg director, 10 percent owner 4340 E KENTUCKY AVE, SUITE 206, GLENDALE CO 80246
Ivo Heiden director, 10 percent owner 2275 HUNTINGTON DRIVE, SUITE 851, SAN MARINO CA 91108